Company Overview and News

36
A Billionaire and a Yogi Team Up to Challenge WhatsApp. No, Not a Joke - Bloomberg

2018-06-08 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
FB UL UN UNLYF ULVR UNLNF

36
A billionaire and a yogi team up on a mobile app. No, not a joke

2018-06-08 livemint
Bengaluru: After hastily withdrawing their new messaging app amid glaring security flaws, an Indian billionaire and his penurious yoga guru partner are about to have another go at it.
FB UL UN UNLYF ULVR UNLNF

142
Jamie Dimon, Warren Buffett urge CEOs to end quarterly earnings forecasts

2018-06-08 livemint
New York: Warren Buffett and Jamie Dimon are doubling down on their plea for corporations to stop providing quarterly earnings guidance.
FB UL UNLYF ULVR UN BP BP.A UNLNF GSK BP.B BRK.A BP BLK GSK BPAQF

36
A billionaire and a yogi team up on a mobile app. No, not a joke

2018-06-08 malaymail
MUMBAI, June 8 — After hastily withdrawing their new messaging app amid glaring security flaws, an Indian billionaire and his penurious yoga guru partner are about to have another go at it.
FB UL UN UNLYF ULVR UNLNF

2
HUL to use Artificial Intelligence to predict your grocery needs

2018-06-08 livemint
Mumbai: The next time you visit your neighbourhood grocery store or call the corner shop for a home delivery, don’t be surprised if your grocery shopkeeper remembers what you ordered the last time and reminds you to restock your Kissan Jam or your detergent and toiletries supply as they are running out and he has an offer. All this and more will soon be possible as the country’s largest consumer packaged goods company, Hindustan Unilever Ltd (HUL), is re-imagining the way we shop at neighbourhood stores.
UL UN UNLYF ULVR 500696 HINDUNILVR UNLNF

2
CCI gives nod to Unilever PLC-Unilever NV deal

2018-06-01 moneycontrol
Fair trade regulator CCI has approved the proposed combination of Unilever PLC and Unilever NV. Unilever PLC and Unilever NV are the two ultimate holding parent companies of the Unilever Group, which is one of the world's leading consumer goods firms.
UL UN UNLYF ULVR UNLNF

77
The 7 Best Long-Term Stocks for Risk-Off Investors

2018-05-29 investorplace
A number of recent studies show that companies who focus on the big picture and long-term success tend to better stocks to buy than those that focus exclusively on the here and now.
ABT UL UN UNLYF ULVR NFLX ISRG ABT UNLNF SPGI PX KHC XYL LNSTY

370
Consumer Products Aren’t Nearly as Safe as You Thought — They’re Dying

2018-05-27 investorplace
Broad markets so far this year have been relatively choppy, particularly since late January peaks. But that hasn’t been the case for large-cap consumer stocks.
PM GIS PG BTI ULVR CPB MNST BATS 4162 FIZZ CHD UNLNF WMT DLTR TSNU KR AMZN CL MKC KO CAG TSN HSY MO BUD SHOP HSYFB UL SJM UN UNLYF MDLZ K BRK.A HRL BREW KHC DG CLX COTY

18
PRESS DIGEST -Wall Street Journal - May 21

2018-05-21 reuters
May 21 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.
UL KR UN UNLYF ULVR AAL KHC SBUX UNLNF

22
Retirement: Should You Buy These Beaten-Down Stocks Now?

2018-05-19 seekingalpha
The stock market has been volatile in 2018. However, some sectors are down more than others.
GIS GEC GE UL UN UNLYF ULVR KHC GNE UNLNF

2
Cream of Wheat maker to hike prices by end of May -CEO

2018-05-16 reuters
NEW YORK (Reuters) - Breakfast staple Cream of Wheat and snack brand Pirate’s Booty will soon cost more as B&G Foods Inc raises list prices for the first time in three years and curbs promotions, the food maker said on Wednesday.
UL UN UNLYF ULVR UNLNF

176
Alphabet Inc Stock Still Has Some Key Concerns

2018-05-16 investorplace
I’ve been relatively skeptical toward Alphabet Inc (NASDAQ:GOOGL, NASDAQ:GOOG) stock for some time now, and as such have missed out on the big run in GOOG stock. While Alphabet stock has been mostly range-bound since late October, it has made some progress. At the least, $1,000 looks like support for GOOG, instead of the resistance that level offered last year.
FB UL PG AMZN GOOGL UN UNLYF ULVR CSCO MSFT GOOG UNLNF

29
Is WisdomTree International Hedged Quality Dividend Growth Fund (IHDG) a Hot ETF Right Now?

2018-05-16 zacks
Making its debut on 05/07/2014, smart beta exchange traded fund WisdomTree International Hedged Quality Dividend Growth Fund (IHDG - Free Report) provides investors broad exposure to the Broad Developed World ETFs category of the U.S. equity market.
HD RHHVF UL UN UNLYF ULVR RHHBY EFA UNLNF IEFA RHHBF

69
7 Consumer Stocks to Sell Now

2018-05-15 investorplace
The first quarter of 2018 has been solid regarding profits. They grew by almost 26% — the best Q1 return in eight years. Unfortunately, investors aren’t buying any of the good news, and that’s especially true of consumer stocks, which are getting hammered year to date.
BUD POOL DECK PG UL UN UNLYF ULVR RL THI UNLNF LW NKE KHC CAG

203
Tracking Gardner Russo & Gardner Portfolio - Q1 2018 Update

2018-05-15 seekingalpha
The top three 13F stakes are Berkshire Hathaway, MasterCard, and Nestle and they add up to one-third of the portfolio.
WFCNP PM CCV ULVR WFC.PRL AXP CCZ BATS WFC.PRJ 4162 RI UNLNF CFRHF WFC.PRT JCDXY WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW CMCSK DEO WFC.PRV MO WFC WFC.WS BUD UL UN SWGAF UNLYF CMCSA MA BRK.A V HEIO SWGAY SWGNF CFRUY CCV.CL BFA MLM JCDXF

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

CUSIP: 904784501